On Friday, Organovo Holdings Inc (ONVO) stock saw a modest uptick, ending the day at $0.44 which represents no change from the prior close of of $0.44. The stock opened at $0.46 and touched a low of ...

Shares of NASDAQ ONVO opened at $0.44 on Wednesday. Organovo has a 12-month low of $0.32 and a 12-month high of $1.74. The company has a market cap of $6.77 million, a P/E ratio of -0.42 and a ...

The presentation entitled “Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agonist FXR314 in Patients with Metabolic Dysfunction-Associated Steatohepatitis: Results from a Phase 2 ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology company specializing in novel treatments for inflammatory bowel disease and other conditions, announced significant findings from ...

Organovo Holdings ( (ONVO) ) just unveiled an update.

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 ...

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

Organovo has lower revenue, but higher earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more ...